March 02, 2026 — 1 articles reviewed
This cycle’s coverage centered on a single but important theme: the longitudinal relationship between regular cannabis use and anxiety outcomes. A decade-long Canadian cohort study drew attention for its dose-dependent findings linking frequent cannabis use to increased anxiety risk in vulnerable populations.
😟 Regular Cannabis Use and Long-Term Anxiety Risk
A longitudinal cohort study from McMaster University, spanning 10 years in a Canadian population, found a dose-dependent association between regular cannabis use and increased anxiety symptoms over time. Frequent users experienced higher rates of anxiety disorder diagnoses compared to non-users, with the risk most pronounced in individuals who already carried baseline anxiety vulnerabilities or a genetic predisposition. The proposed mechanism involves dysregulation of the hypothalamic-pituitary-adrenal axis and disrupted endocannabinoid signaling in brain regions governing emotional regulation. This is clinically significant because many patients perceive cannabis as an anxiolytic based on genuine short-term relief, yet the data suggest that sustained use may paradoxically raise baseline anxiety and lower the threshold for disorder onset. The practical takeaway for clinicians is clear: risk stratification matters, and patients with personal or family histories of anxiety disorders deserve direct counseling about this measurable long-term risk before initiating or continuing regular cannabis use.
- #72Worrying link between cannabis use and anxiety revealed in new study and the impact … – UNILAD
Short-term relief is not the same as long-term safety, and this study is a strong reminder that patient selection and dosing discipline are not optional in cannabis medicine. When patients tell us cannabis “helps their anxiety,” our job is to hold space for that experience while also ensuring they understand what the longitudinal evidence actually shows.